CAS 1093746-29-2

Formula: C35H36ClNO3S

InChI: InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1/i1D3,2D3

InChI key: UCHDWCPVSPXUMX-ZCAOFVIOSA-N

SMILES: [2H]C([2H])([2H])C(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)(C([2H])([2H])[2H])O

Montelukast-d6

CAS: 1093746-29-2

Formula: C₃₅H₃₀D₆ClNO₃S

Color and Shape: Yellow Solid

Molecular weight: 592.22

Ref: 4Z-M-305

Montelukast-d6 Sodium Salt

Controlled Product

CAS: 1093746-29-2, 151767-02-1, 158966-92-8

Formula: C₃₅H₂₉D₆ClNNaO₃S

Color and Shape: Neat

Molecular weight: 614.2

Ref: TR-M568002

Montelukast Impurity 32

CAS: 1093746-29-2, 158966-92-8

Formula: C₂₉H₂₆ClNO

Molecular weight: 439.98

Ref: 4Z-M-3059

Montelukast-D6

CAS: 1093746-29-2

Montelukast-D6 is a deuterated compound of Montelukast. Montelukast (T1677) has a CAS number of 158966-92-8. Montelukast (T1677) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Formula: C₃₅H₃₀D₆ClNO₃S

Molecular weight: 592.22

Ref: TM-TMIJ-0329

Montelukast-d6

CAS: 1093746-29-2

Formula: C₃₅H₃₆ClNO₃S

Molecular weight: 592.2

Ref: BE-RMCM248044

Montelukast-d6

CAS: 1093746-29-2

Montelukast-d6 is an analog of Montelukast, a drug used for the treatment of asthma and allergic rhinitis. Montelukast-d6 has been shown to have anticancer properties by inhibiting the activity of certain kinases that are involved in cancer cell growth and proliferation. This drug has been found to induce apoptosis in human cancer cells, making it a promising candidate for cancer therapy. Montelukast-d6 is also a potent inhibitor of protein kinases, which play a key role in tumor development and progression. This inhibitor has been shown to inhibit the growth of tumors in mice, suggesting its potential as an effective anticancer agent. Montelukast-d6 can be detected in urine samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques, making it useful for monitoring drug levels during clinical trials or treatment.

Formula: C₃₅H₃₆ClNO₃S

Purity: Min. 95%

Molecular weight: 592.2 g/mol

Ref: 3D-TTB74629